HROW
Harrow Health, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 7.50K | $231,062 | n/a | n/a |
| Q2 2026 | 80 | 0 | 11.44M | $485.62M | +8 | −8 |
| Q1 2026 | 83 | -4 | 11.18M | $394.57M | +6 | −10 |
| Q4 2025 | 87 | 0 | 11.51M | $563.95M | +1 | −1 |
| Q3 2025 | 15 | -1 | 7.56M | $364.09M | +1 | −2 |
| Q2 2025 | 13 | 0 | 7.79M | $237.82M | n/a | n/a |
| Q1 2025 | 10 | +1 | 3.25M | $86.47M | +1 | n/a |
| Q4 2024 | 9 | 0 | 2.94M | $98.57M | n/a | n/a |
| Q3 2024 | 8 | +1 | 2.10M | $94.28M | +2 | −1 |
| Q2 2024 | 7 | n/a | 1.47M | $30.78M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assenagon Asset Management S.A. | 7.50K | -50.0% | $231,062 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 216 holders, 21.37M shares, $751.67M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 11.25K sh · $450,000
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology